The DOI matches its Crossref record.
Prognostic significance of c‐Met expression in glioblastomas
Open accessAbstract
BACKGROUD: The authors investigated whether expression of c‐Met protein in glioblastomas is associated with overall survival and biologic features representing tumor invasiveness in patients with glioblastomas. METHODS: Paraffin‐embedded specimens of glioblastomas from 62 patients treated in a single institution were assessed by immunohistochemical (IHC) analysis of c‐Met expression. On the basis of the clinical data for these patients, the association between c‐Met expression and clinicobiologic features representing tumor invasiveness was analyzed. RESULTS: c‐Met overexpression was detected in 29.0% (18 of 62) of glioblastomas. In patients with c‐Met overexpression, the median survival was 11.7 months (95% confidence interval [95% CI], 9.9 months‐13.5 months), compared with a median survival of 14.3 months (95% CI, 7.6 months‐21.0 months) for patients whose tumors had no or little expression of c‐Met (P = .031). On the radiographic analysis, 9 of 18 patients (50%) with tumors overexpressing c‐Met demonstrated invasive and multifocal lesions on the initial magnetic resonance images, whereas only 9 of 44 patients (20.5%) with tumors that expressed no or little c‐Met demonstrated these features (P = .030). Using immunohistochemistry, we also found a significant association between c‐Met expression and matrix metalloproteinase‐2,‐9 (P = .020 and P = .013). Furthermore, Myc overexpression was found to be closely correlated with c‐Met overexpression on IHC analysis (P = .004). CONCLUSIONS: The authors suggest that c‐Met overexpression is associated with shorter survival time and poor treatment response in glioblastomas, the mechanism for which is elevated tumor invasiveness on the molecular and clinical phenotypes. This implies that more effective therapeutic strategies targeting c‐Met receptors may have important clinical implication. Cancer 2009. © 2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Emerging insights into the molecular and cellular basis of glioblastoma
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 565
Ovarian cancer: Current status and strategies for improving therapeutic outcomes
Chandra, A., Pius, C., Nabeel, M., Nair, M., Vishwanatha, J. K., Ahmad, S., & Basha, R. (2019) · Cancer Medicine · doi:10.1002/cam4.2560 · Cited by 449
Sennino, B., Ishiguro-Oonuma, T., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V., Tabruyn, S. P., You, W.-K., Chapman, H. A., Christensen, J. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0240 · Cited by 408
Targeting cellular pathways in glioblastoma multiforme
Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 344
Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets
Taylor, O. G., Brzozowski, J. S., & Skelding, K. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00963 · Cited by 322
MET: a promising anticancer therapeutic target
Peters, S., & Adjei, A. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.71 · Cited by 280
WNT signaling in glioblastoma and therapeutic opportunities
Lee, Y., Lee, J.-K., Ahn, S. H., Lee, J., & Nam, D.-H. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2015.140 · Cited by 273
Self-citationInhibition of c-Met Reduces Lymphatic Metastasis in RIP-Tag2 Transgenic Mice
Sennino, B., Ishiguro-Oonuma, T., Schriver, B. J., Christensen, J. G., & McDonald, D. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2160 · Cited by 60
Zhao, C., Guo, R., Guan, F., Ma, S., Li, M., Wu, J., Liu, X., Li, H., & Yang, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-65331-3 · Cited by 51
Metadata
- Authors
- Kong, D., Song, S., Kim, D., Joo, K. M., Yoo, J., Koh, J. S., Dong, S. M., Suh, Y., Lee, J., Park, K., Kim, J. H., & Nam, D.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-12-29
- Volume
- 115
- Issue
- 1
- Pages
- 140-148
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1544392741
- Cited by
- 187
- References
- 0
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.